Research programme: LNA antisense oligonucleotides - Enzon/Roche

Drug Profile

Research programme: LNA antisense oligonucleotides - Enzon/Roche

Alternative Names: Cur 813; EZN-3889; EZN-3892; EZN-3920; EZN-4150; EZN-4482; EZN-4496; PEG-LNA-ON; SPC2004; SPC3920

Latest Information Update: 04 Dec 2014

Price : $50

At a glance

  • Originator Santaris Pharma
  • Developer Roche
  • Class Antisense oligonucleotides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Androgen receptor antagonists; Antisense RNA inhibitors; Beta catenin inhibitors; ERBB-3 receptor modulators; Proto-oncogene protein c-bcl-2 modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Oct 2013 Enzon Pharmaceuticals terminates its licence for the research programme
  • 17 Jul 2012 Preclinical development is ongoing for cancer in the USA
  • 16 Nov 2011 Pharmacodynamics data from preclinical trials in Cancer presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top